CpG-oligodeoxynucleotide Adjuvants for Immune Checkpoint Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy using PD-1/PD-L1 monoclonal antibodies has a low response rate in patients with solid tumors, and CpG-oligodeoxynucleotides (CpG-ODNs) have shown promise but lack FDA approval for cancer therapy.
Innovation Solution
Combining an immune checkpoint blockade, such as anti-PD-1, anti-PD-L1, or anti-CTLA4 antibodies, with an adjuvant composition comprising specific CpG-oligodeoxynucleotides like CpG-1585, CpG-2216, CpG-1826, CpG-2006, CpG-2722, or CpG-M362, to enhance anti-tumor immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1/PD-L1 monoclonal antibodies are used for cancer immunotherapy, then immune checkpoint blockade is achieved, but the response rate in patients with solid tumors remains low (less than 30%)
Solution Approach 1:
The patent combines immune checkpoint blockade (anti-PD-1/PD-L1 antibodies) with CpG-oligodeoxynucleotide adjuvants to create a synergistic therapeutic approach. This combination merges two different mechanisms of action: checkpoint inhibition to release T cell brakes and TLR9 activation to stimulate innate and adaptive immune responses, thereby overcoming the limited response rate of monotherapy and improving overall treatment efficacy in solid tumors
2Reliability
If CpG-oligodeoxynucleotides are used as therapeutic agents, then anti-tumor immune response is activated, but FDA approval has not been achieved yet
Solution Approach 1:
The patent positions CpG-oligodeoxynucleotides as adjuvants that mediate and enhance the effect of immune checkpoint blockade therapy. By using CpG-ODNs as intermediary agents to stimulate TLR9 and activate immune responses, the invention creates a more robust and reliable anti-tumor effect that may facilitate regulatory approval through demonstrated superior clinical benefit
3Reliability
If combination therapy with immune checkpoint blockade and CpG-oligodeoxynucleotide adjuvant is administered, then cytokine production and T cell infiltration are enhanced, but treatment complexity increases
Solution Approach 1:
The patent segments the immunotherapy approach into two distinct components with complementary functions: immune checkpoint blockade to inhibit suppressive signals and CpG-oligodeoxynucleotide adjuvants to activate immune responses. This segmentation allows each component to be optimized independently while working synergistically together, managing treatment complexity through modular design
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy effectively induces cytokine production, increases CD8+ T cell infiltration, and suppresses tumor growth, demonstrating a cooperative effect in overcoming immunotherapy resistance and improving treatment efficacy in cancers like melanoma and non-small cell lung cancer.
Implementation Method 1
CpG-oligodeoxynucleotides (CpG-ODNs) are synthetic activator of toll-like receptor 9 (TLR9) and TLR21 in different species. The activation of mammalian TLR9 by CpG-ODNs induces immune responses including an innate immune response elicited within hours after CpG-ODN stimulation followed by a second phase of adaptive immune response occurred several days later.
Implementation Method 2
PD-1 controls the late immune response of T cells in peripheral tissues, as its ligands are mainly expressed in nonlymphoid tissues. A variety of PD-1/PD-L1 monoclonal antibodies have been developed for anti-tumors by immune checkpoint blockade.
Data Source
AI summary
The present invention discloses a combinational therapy for enhancing efficacy of immune checkpoint blockade for tumors with immune suppressive microenvironment. More specifically, this combination therapy involves the treatment of cancer through immune checkpoint inhibitors and CpG-oligodeoxynucleotides.